The ARAP1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the ARAP1 gene is disrupted to eliminate protein function. This heterogeneous model, derived from the HT29 human colorectal adenocarcinoma line, enables robust population-level loss-of-function studies of ARAP1??s cellular roles. The polyclonal nature ensures broad representation of editing outcomes, avoiding clonal artifacts.
The HT29 cell line originates from a primary colorectal adenocarcinoma of a 44-year-old female patient. It displays adherent epithelial growth, secretes mucins, and retains the capacity to differentiate in vitro, making it a faithful model of intestinal epithelium. HT29 cells are foundational in colorectal cancer research, employed in investigations of drug resistance, metastatic mechanisms, and epithelial barrier function, thus providing a physiologically relevant host for ARAP1 knockout analysis.
ARAP1 serves as a dual GTPase-activating protein for Arf1/5 and RhoA, coupling endosomal trafficking with actin cytoskeleton dynamics. It is recruited to PIP3-enriched endosomes upon EGFR and PI3K activation, where it interacts with CIN85 and ANXA2. Through its GAP activities on Arf1, Arf5, and RhoA, ARAP1 coordinates clathrin-dependent endocytic recycling, focal adhesion turnover, and cell migration, transmitting signals to downstream effectors such as ROCK, myosin, and actin.
In the HT29 colorectal cancer context, ARAP1 knockout permits dissection of its contributions to EGFR trafficking, cell adhesion, and migration. Since ARAP1 integrates growth factor signals with actin remodeling, its loss likely impairs endocytic recycling of EGFR and focal adhesion dynamics, potentially altering invasive behavior. This model is valuable for exploring how disrupted ARAP1 affects colorectal adenocarcinoma cell motility, junctional integrity, and therapeutic response.
These polyclonal knockout cells are suitable for a range of functional assays: western blotting to confirm ARAP1 absence, immunofluorescence localization of actin and associated proteins, EGF uptake and recycling kinetics, RhoA and Arf1 activation assays, cell migration and invasion chambers, and phospho-signaling analyses. The model supports detailed investigations of EGFR?CPI3K signaling, endosomal trafficking, cytoskeletal regulation, and drug sensitivity profiling. RNA-seq can be used to identify transcriptional programs altered upon ARAP1 disruption. For further technical information, please contact Ascent Research.
